# Sanara MedTech (SMTI) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SMTI
## Company Profile
- Ticker: SMTI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 34.38 USD
- Market cap: 194825980.94000003 USD
- Last updated: 2026-08-11
## Business Overview
### Surgical Wound and Tissue Repair
Sanara MedTech develops and commercializes products intended to improve surgical healing and reduce complications and healthcare costs.
### Soft-Tissue Repair Portfolio
The company’s products address wound cleansing, infection management, extracellular matrix support, and tissue repair across surgical specialties.
### Procedure-Based Commercial Model
Sanara sells through hospital and surgeon relationships, with revenue driven by procedure volumes, product adoption, and expansion of its direct commercial organization.
### Technology Acquisition Strategy
The company supplements internal development with licensed and acquired technologies that can be distributed through its existing surgical channel.
## Why The Stock Is Moving

As of Aug 11, 2026, SMTI closed up 0.38% at $34.38. No new same-company headline was identified in the current news window.

## Future Catalysts

- Sanara MedTech’s catalysts are wound-care and surgical-product sales, along with continued execution in specialty care. It is a steady operating story, so the market will focus on adoption and margin discipline.

## Recent News
- 2026-05-11 20:50 EST — [Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-first-quarter-2026-financial-results-unaudited-60a52bab) — Source: Sanara MedTech
- 2026-04-14 11:30 EST — [Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026-6f13f45d) — Source: Sanara MedTech
- 2026-03-24 11:00 EST — [Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-fourth-quarter-unaudited-and-full-year-2025-financial-4054944c) — Source: Sanara MedTech
- 2026-03-11 11:30 EST — [Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-announces-publication-of-peer-reviewed-study-evaluating-the-e-7ca921f2) — Source: Sanara MedTech
- 2026-03-03 12:30 EST — [Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-df95bb20) — Source: Sanara MedTech